Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 8/20 | 0.47 |
| ▸ | MKNK2 | Q9HBH9 | 8/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | KIF11 | P52732 | 1/20 | 0.43 |
| ▸ | NAAA | Q02083 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.42 |
| ▸ | MMP12 | P39900 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 1/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | BRS3 | P32247 | 1/20 | 0.40 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1676927 | 1.00 | MKNK1 (0.47) | MKNK1MKNK2CYP2A6KIF11NAAA | |
| SCHEMBL539487 | 0.86 | MKNK1 (0.50) | MKNK1MKNK2CYP2A6NAAAMMP12 | |
| SCHEMBL25318441 | 0.86 | SLC7A5 (0.46) | — | |
| SCHEMBL30476014 | 0.86 | SLC7A5 (0.46) | — | |
| Hydrochloric Acid SCHEMBL539486 | 0.85 | MKNK1 (0.49) | MKNK1MKNK2CYP2A6NAAAMMP12 | |
| Hydrochloric Acid SCHEMBL539488 | 0.85 | MKNK1 (0.49) | MKNK1MKNK2CYP2A6NAAAMMP12 | |
| Hydrochloric Acid SCHEMBL27782845 | 0.84 | SRR (0.51) | — | |
| SCHEMBL7337394 | 0.81 | ACACB (0.56) | — | |
| SCHEMBL7337381 | 0.81 | ACACB (0.56) | — | |
| SCHEMBL1676744 | 0.81 | MKNK1 (0.45) | MKNK1MKNK2CYP2A6NAAAMMP12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098477-A1 | Method Of Producing Compound Having Anti-Hcv Activity | CHUGAI SEIYAKU KABUSHIKI KAISHA | 2011-04-28 | — | — | US | disclosed |
| US-20110098477-A1 | Method Of Producing Compound Having Anti-Hcv Activity | CHUGAI SEIYAKU KABUSHIKI KAISHA | 2011-04-28 | — | — | US | disclosed |
| US-20110098477-A1 | Method Of Producing Compound Having Anti-Hcv Activity | CHUGAI SEIYAKU KABUSHIKI KAISHA | 2011-04-28 | — | — | US | disclosed |
| EP-1908846-A1 | METHOD OF PRODUCING COMPOUND HAVING ANTI-HCV ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098477-A1 | Method Of Producing Compound Having Anti-Hcv Activity | ERG28, HCCS, BCAT2 | MKNK1 2163/4885MKNK2 2897/4885CYP2A6 489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.